Skip to main content
. 2021 Sep 7;11:732214. doi: 10.3389/fonc.2021.732214

Figure 3.

Figure 3

Forest plots of hazard ratios comparing overall survival between patients treated with anti-PD-1/PD-L1-based therapy or non-ICI therapy according to age, sex, and histological type. PD-1, programmed death-1; PD-L1, programmed death-ligand 1; ICI, immune checkpoint inhibitor.